Skip to content

Checked

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

NCT07225270 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 3
Interventional
Planned enrollment
544
Participants, all sites
U.S. sites
9
In 7 states

Study details

Conditions
Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
Sponsor
Genmab (Industry)
Ages
18 years and older
Sex
Female only
Healthy volunteers
Not accepted
Start
04/03/2026
Primary completion (expected)
October 2028
Last updated by sponsor
10/06/2026

Full eligibility rules, contacts and site names: NCT07225270 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • Florida: Miami, Sarasota
  • Maryland: Towson
  • Missouri: Columbia
  • Nebraska: Omaha
  • North Carolina: Charlotte
  • Ohio: Centerville, Columbus
  • Pennsylvania: Horsham

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/06/2026